Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study

Comprehensive TCM treatments combined with chemotherapy for advanced non-small cell lung cancer

(2021) Zhiwei Xiao et al.   MEDICINE

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma

(2020) Hai-ying Wang et al.   OncoTargets and Therapy

Yiqi Chutan Tang Reduces Gefitinib‐Induced Drug Resistance in Non‐Small‐Cell Lung Cancer by Targeting Apoptosis and Autophagy

(2019) Jue Zhang et al.   CYTOMETRY PART A

Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer

(2019) Kathryn C. Arbour et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)

(2018) Baohui Han et al.   BRITISH JOURNAL OF CANCER

Anlotinib: First Global Approval

(2018) Yahiya Y. Syed   DRUGS

Effects of Kanglaite Injection on Serum miRNA-21 in Patients with Advanced Lung Cancer

(2018) Yue Wu et al.   MEDICAL SCIENCE MONITOR

Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development

(2018) Guoshuang Shen et al.   Journal of Hematology & Oncology

Angiogenesis Inhibitors in NSCLC

(2017) Anna Manzo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Patient-reported outcome measures (PROMs) in the management of lung cancer: A systematic review

(2017) Youssef Ben Bouazza et al.   LUNG CANCER

Structural characterization and in vitro antitumor activity of an acidic polysaccharide from Angelica sinensis (Oliv.) Diels

(2016) Yu Zhang et al.   CARBOHYDRATE POLYMERS

Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards

(2016) Andrew Bottomley et al.   LANCET ONCOLOGY

BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer

(2015) Caicun Zhou et al.   JOURNAL OF CLINICAL ONCOLOGY

Cantharidin inhibits angiogenesis by suppressing VEGF-induced JAK1/STAT3, ERK and AKT signaling pathways

(2014) Ting Wang et al.   ARCHIVES OF PHARMACAL RESEARCH

Expression of prolyl 4-hydroxylase beta-polypeptide in non-small cell lung cancer treated with Chinese medicines

(2014) Shu-mei Wang et al.   Chinese Journal of Integrative Medicine

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

(2009) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Lung Cancer

(2008) Roy S. Herbst et al.   NEW ENGLAND JOURNAL OF MEDICINE